News for Incyte Corporation (I1NC34.SA)

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase

Exploring the robust pipeline and commercial strategies of Syndax Pharmaceuticals Inc (SNDX).Delving into the financial intricacies and growth trajectory of SN

The following slide deck was published by Incyte Corporation in conjunction with their 2025 Q1 earnings call.

Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ETCompany ParticipantsGreg Shertzer - Director of Investor...

Incyte (Nasdaq:INCY) today reports 2025 first quarter financial results, and provides a status update on the Company's clinical development portfolio.

Incyte's Q1 2025 revenues reached $1,053 million, a 20% year-over-year increase. Jakafi (ruxolitinib) net product revenue rose by 24% to $709 million in

Incyte (INCY) to present new data from its early-stage oncology portfolio at AACR 2025. Highlights include advancements in treatments for myeloprolifera

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck for the India's largest pharmaceutical company to launch its alopecia drug Leqselvi in the United States.

Stocks including TCS, Tata Steel, GAIL (India), Infosys, BHEL, Sun Pharma, NBCC (India), Bharti Hexacom, Eternal, Aurobindo Pharma and TARC will be in the spotlight on Friday, April 10.

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions on the launch on April 9, Sun Pharma said in a regulatory filing.

Incyte (INCY) will announce its Q1 2025 financial results on April 29, 2025, at 7:00 a.m. ET. The company will hold a conference call and webcast at 8:0

Sun Pharmaceutical Industries Ltd on Thursday said a US court has ruled in its favour and vacated a preliminary injunction effective immediately removing restrictions on it launching LEQSELVI, a drug used to treat autoimmune disorder that causes patchy hair loss. Sun Pharma had been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib).

Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff.

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase

**media[572458]**

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program up

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires.

Shares of biopharmaceutical company Incyte Corporation (INCY) experienced a notable decline, falling 7.32%. This drop followed the release of the phase three tr